Improving awareness, diagnosis and management of invasive fungal infections in Ghana: establishment of the Ghana Medical Mycology Society

Bright K. Ocansey1,*, Edmund A. Dadzie2, Stephen K. Edufu3, Martin Agyei4, Mary-Magdalene Osei5, Peter Pulpam6,7, Isabella Asamoah7, Rita O. Oladele8,9, Iriagbonse I. Osaigbovo9, Jane S. Afriyie-Mensah6,7, Japheth A. Opintan9,10, Samuel Essien-Baidoo10, Arunaloke Chakrabarti11, Martin Hoenig12,13, David W. Denning1 and Malcolm D. Richardson1,14

1Division of Evolution, Infection and Genomics, Faculty of Biology, Medicine and Health, University of Manchester, Manchester M13 9NT, UK
2Department of Health and Allied Sciences, Baldwin University College, Accra GA-082, Ghana
3Department of Medical Laboratory Sciences, School of Biomedical and Allied Health Sciences, University of Ghana, Accra GA-337, Ghana
4Department of Medicine, School of Medical Sciences, Kwame Nkrumah University of Science and Technology, Kumasi AK-448, Ghana
5Department of Medical Microbiology, University of Ghana Medical School, Accra GA-270, Ghana
6Department of Medicine and Therapeutics, University of Ghana Medical School, Accra GA-221, Ghana
7Department of Medicine and Therapeutics, Korle-Bu Teaching Hospital, Accra GA-221, Ghana
8Department of Medical Microbiology, College of Medicine, University of Lagos, Lagos 101017, Nigeria
9Department of Medical Microbiology, College of Medical Sciences, University of Benin, Benin City 92033, Nigeria
10Department of Medical Laboratory Sciences, School of Allied Health Sciences, University of Cape Coast, Cape Coast CC-071, Ghana
11Department of Medical Microbiology, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India
12Section of Infectious Diseases and Tropical Medicine, Division of Pulmonology, Medical University of Graz, Graz 8036, Austria
13Division of Infectious Diseases and Global Public Health, University of California San Diego, San Diego, CA 92039-0021, USA
14Mycology Reference Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester M23 9LT, UK

*To whom correspondence should be addressed. Bright K. Ocansey, BSc, Division of Evolution, Infection and Genomics, Faculty of Biology, Medicine and Health, University of Manchester, Core Technology Facility, Grafton Street, Manchester M13 9NT. Tel: +44 7538311942; E-mail: obkatey91@gmail.com or bright.ocansey@postgrad.manchester.ac.uk

Abstract

Invasive fungal infections (IFIs) and medical mycology receive little attention in Ghana. However, the present evolution of biomarker assays for IFIs, offers an opportunity for an increased access to fungal laboratory testing in resource-limited settings, and probably make a case for availability of essential antifungal agents. Using surveys and personal communications, the state of medical mycology and IFI in Ghana were highlighted. Inadequate awareness and insufficient access to fungal diagnostics and therapeutics were identified as the key challenges; the establishment of the Ghana Medical Mycology Society was discussed, and recommendations were made to improve the status quo.

Lay Summary

Invasive fungal infections (IFIs) receive little attention in Ghana, despite its growing relevance globally. Using surveys and personal communications, the main challenges were identified, and the formation of the Ghana Medical Mycology Society was discussed as a tool to improve the status quo.

Keywords: Ghana, invasive fungal infections, diagnostics, antifungal agents, research

Introduction

 Globally, the burden of invasive fungal infections (IFIs) continue to increase due to the expansion of the population at risk and emerging risk groups including the coronavirus disease 2019 (COVID-19).1,2 Recent concerns are, increasing antifungal resistance, multi-drug-resistant Candida auris and emergence of rare infections.3–5 Notwithstanding, IFIs receive little attention in many parts of the world, particularly Africa that is disproportionately affected by IFIs due to the HIV and tuberculosis epidemic and the tropical climate.6 The Leading International Fungal Education (LIFE) and Global Action for Fungal Infections (GAFFI) burden-estimate projects have stimulated interest in medical mycology in many African countries including Ghana. The evolution of rapid and simple fungal biomarker assays and access programs for essential antifungal agents offers a unique opportunity for low- and middle-income countries (LMICs) to improve diagnosis and management of patients suffering from IFIs. In this report, we highlight the current state of IFIs and medical mycology in Ghana, by identifying the key challenges and discuss the formation of the Ghana Medical Mycology Society (GMMS),...
formerly Ghana Medical Mycology Group (GMMG) and recommendations to improve the status quo.

Methods

Information was gathered from a previously published study on IFIs in Ghana,7 findings from three unpublished gap analysis surveys to evaluate IFI awareness among health sciences students, availability and accessibility to fungal laboratory tests and essential antifungal agents in Ghana, and personal communications with relevant stakeholders were used to prepare this report.

Results and discussion

In 2019, about 4% of the Ghanaian population was estimated to suffer from serious fungal infections yearly, including over 35,000 affected by IFIs.7 This estimate may not represent a true reflection of a burden of IFIs in Ghana, because some of the prevalence or incidence rates used were borrowed from regional and global studies due to absence of local epidemiological data. The study also reported that, data on IFIs generally consist of few sporadic case reports where diagnoses were mostly made post-mortem, probably indicating a low index of suspicion.7 Furthermore, in some of the case reports, the authors bemoaned the insufficient clinical suspicion and inaccessibility to critical fungal laboratory tests and essential antifungal agents. Real life epidemiological studies are needed for a true burden to be appreciated. For example, a recently published study revealed that disseminated histoplasmosis may be more common than cryptococcal meningitis in Ghana contradicting the findings from the model study.8 The few epidemiological studies are often spearheaded by foreign clinicians and the upskilled diagnostic capacity declines after the study.9,10 Going forward, study investigators must engage policy makers and clinical leads towards drawing a framework for implementation and ensuring the integration of the research laboratory testing into clinical practice.

There are currently no surveillance or case notification programs for any IFI in Ghana. Meanwhile, the steady prevalence rate (∼2.0%) of HIV, TB burden (286/100,000), increase in cancer rates (2000–5000 increase per year in the last decade), gradual introduction of kidney (over 20 live donor transplants in the last decade) and stem cell transplant procedures and expanding ICU beds (149 beds, over 100% increase since the COVID-19 pandemic) also makes way for the significant occurrence of IFIs.11–15 Unpublished data from three gap analysis surveys in Ghana, suggest that awareness on IFIs among final year health sciences students was inadequate and the availability of fungal diagnostics and antifungal drugs (Table 1) is poor, particularly in relation to the WHO recommendations.16–19

In Ghana, medical mycology is underdeveloped and attracts little interest in academia and professional practice. Teaching hours allocated for mycology are limited and options for specialization in mycology are almost non-existent. Moreover, numbers of educators, researchers, and trainers are also woefully inadequate. Unlike, plant mycology, there are presently no established medical mycology units/divisions in health/medical institutions in Ghana.

To increase awareness, a non-governmental organization, Fungal Infections Kare Initiative (FIKI) Ghana was founded in 2019 led by BKO and EAD. FIKI Ghana organized two sensitization seminars with the second inaugurating the GMMG. The foundation also facilitated the three gap analysis surveys mentioned previously with financial support from the Fungal Infection Trust (FIT). FIKI Ghana also established collaborative links with the International Society for Human and Animal Mycology (ISHAM), Centre for Disease Control (CDC) Mycotic Disease Branch, UK National Aspergillosis Centre, and Mycology Reference Centre, Manchester that have been extended to GMMS and continue to strengthen it. The role of professional networks in the advancement of unpopular fields such as medical mycology cannot be overemphasized and strongly demonstrated by the Medical Mycology Society of Nigeria (MMSN) that charted a model on how societies can contribute to combating IFIs in LMICs.20

GMMS is a network of multidisciplinary cadre of health-care professionals (HCP) mainly clinicians and scientists as well as health science researchers and academics with interest in medical mycology or fungal infections. The current membership includes infectious disease specialists/consultants,

Table 1. Availability of fungal diagnostics and essential antifungal agents in Ghana.

| Test                                      | Availability | On Ghana EDL | On WHO EDL16,17 |
|-------------------------------------------|--------------|--------------|-----------------|
| Direct microscopy (KOH)                   | Often        | N/A          | Yes             |
| Histopathology (fungal stains)            | Occasionally | N/A          | Yes             |
| Fungal culture                            | Rarely       | N/A          | Yes             |
| Immunoassay                               | Rarely       | N/A          | Yes (Aspergillus Ag and Ab, CrAg, Histoplasma GM) |
| Molecular                                 | Rarely       | N/A          | Yes and WHO GLASS programme (Candida spp.) |
| Antifungal susceptibility                  | Rarely       | N/A          |                 |

| Antifungal agent                           | Availability | On Ghana EML18 | On WHO EML19 |
|-------------------------------------------|--------------|----------------|--------------|
| Fluconazole                               | Often        | Yes            | Yes          |
| Itraconazole                              | Occasionally | Yes            | Yes          |
| Amphotericin B                            | Rarely       | No             | Yes          |
| Flucytosine                               | Rarely       | No             | Yes          |
| Voriconazole                              | Rarely       | No             | Yes          |
| Natamycin                                 | Rarely       | No             | Yes          |

EDL-essential diagnostics list, N/A—not applicable (because Ghana has no EDL currently), KOH-Potassium hydroxide, Ag-antigen, Ab-antibody, CrAg-Cryptococcal antigen, GM- Galactomannan, PCR-polymerase chain reaction, GLASS-Global Antimicrobial Resistance Surveillance System, EML- essential medicines list.
dramatologists, clinical microbiologists, medical laboratory scientists, pulmonologists, and pharmacists.

GMMS has a vision to reduce illness and death associated with fungal diseases in Ghana. The GMMS’ mission is to increase awareness, build diagnostic and therapeutic capacity, campaign for access to critical diagnostics and antifungal agents, drive research, and influence the gradual integration of the discipline into health systems in Ghana, mainly through an eight-itemized activity schedule (Table 2). The society also circulates advocacy leaflets and disseminates links of free training, educational, and clinical resources. Since its inception in February 2020, GMMS has successfully organized several meetings and activities in three consecutive years. The society has also occasionally served as a platform to provide guidance on diagnosis and treatment of IFIs to Ghanaian clinicians and scientists with support from our international affiliations. GMMS continuously shares participation details of meetings in the field of medical mycology to members and urges to disseminate to colleagues. Members are constantly encouraged to register with ISHAM, to take advantage of associated benefits and currently have 20% of our members registered with ISHAM.

The recommended framework for a short term, is for the government to adopt and upgrade the WHO Essential Diagnostic and Medicine lists respectively, particularly in the tertiary hospitals. Also, training of technical laboratory staff and clinicians in these institutions will lay a solid foundation for the integration of clinical mycology in the healthcare system broadly. From a practical perspective, the easiest tests to adopt are the lateral flow assays, especially cryptococcal and Histoplasma antigen and Aspergillus antibody in HIV and TB control programmes, respectively. From this start, direct microscopy and fungal culture could be the next step. From a public health and clinical perspective, undertaking a surveillance of key fungal diseases through a hospital and laboratory reporting network, would be valuable in improving local epidemiology and encouraging and attracting clinical research with international funding.

**Conclusion**

Ghana is challenged with the underrecognition of IFIs and underdevelopment of medical mycology. In face of the numerous challenges, the GMMS remains resolute and optimistic to act as a major driver to increase awareness, advance the diagnostic and therapeutic skills of clinicians and scientists, improve access to fungal diagnostics and antifungal drugs, and champion the integration medical mycology into health systems in Ghana.

**Funding**

None

**Declaration of interest**

The authors declare no potential conflict of interest.

**References**

1. Fausto A, Rodrigues ML, Coelho C. The still underestimated problem of fungal diseases worldwide. *Front Microbiol.* 2019; 10: 1–5.
2. Song G, Liang G, Liu W. Fungal co-infections associated with global COVID-19 pandemic: a clinical and diagnostic perspective from China. *Mycopathologia.* 2020; 185: 599–606.
3. Fisher MC, Alastruey-Izquierdo A, Berman J et al. Tackling the emerging threat of antifungal resistance to human health. *Nat Rev Microbiol.* 2022; 1–5.
4. Hoenigl M, Salmantont-Garcia J, Walsh TJ et al. Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of medical mycology in cooperation with the International Society for Human and Animal Mycology and the American Society of Microbiology. *Lancet Infect Dis.* 2021, 21: e246–e257.
5. Chen SC, Perfect J, Colombo AL et al. Global guideline for the diagnosis and management of rare yeast infections: an initiative of the ECMM in cooperation with ISHAM and ASM. *Lancet Infect Dis.* 2021; 21: e375–e386.
6. Oladele RO, Akase IE, Fahal AH et al. Bridging the knowledge gap on mycoses in Africa: setting up a pan-African mycology working group. *Mycoses.* 2020; 63: 244–249.
7. Ocsey BK, Peseuw GA, Codjoe FS et al. Estimated burden of serious fungal infections in Ghana. *J Fungi.* 2019; 5: 1–15.
8. Ocsey BK, Otoo B, Asamoah I et al. Cryptococcal and histoplasma antigen screening among people with human immunodeficiency virus in Ghana and comparative analysis of ODX histoplasma lateral flow assay and IMMY histoplasma enzyme immunoassay. *Open Forum Infect Dis.* 2022; 9: ofac277. Oxford University Press.
9. Mamoojee Y, Shakoor S, Gorton RL et al. Low seroprevalence of cryptococcal antigenemia in patients with advanced HIV infection enrolling in an antiretroviral programme in Ghana. *Trop Med Int Health.* 2011; 16: 53–56.
10. Leck AK, Thomas PA, Hagan M et al. Aetiology of suppurative corneal ulcers in Ghana and South India, and epidemiology of fungal keratitis. *Br J Ophthalmol.* 2002; 86: 1211–1215.
11. Ali H, Amoyaw F, Baden D et al. Ghana’s HIV epidemic and PEPFAR’s contribution towards epidemic control. *Ghana Med J.* 2019; 53: 59–62.
12. Challenge Facility for Civil Society Ghana National TB Voice Network TB in Ghana. Accessed December 21, 2021. [www.tbvoice network.net](http://www.tbvoice network.net).  
13. Statista. *Number of cancer cases in Ghana from 2010 to 2019*. Accessed August 26, 2022. [https://www.statista.com/statistics/1283497/cancer-cases-in-ghana/](https://www.statista.com/statistics/1283497/cancer-cases-in-ghana/).
14. Boima V, Amissah-Arthur MB, Yorke E et al. Determinants of willingness to accept kidney transplantation among chronic kidney disease patients in Ghana. *BMC nephrol.* 2021; 22: 1–2.

15. Siaw-Frimpong M, Touray S, Sefa N. Capacity of intensive care units in Ghana. *J Crit Care.* 2021; 61: 76–81.

16. World Health Organization. *The Selection and Use of Essential in Vitro Diagnostics,* 2021; 1031. https://apps.who.int/iris/bitstream/handle/10665/339064/9789240019102-eng.pdf?sequence=1&isAllowed=y.

17. Global Antimicrobial Resistance Surveillance System (GLASS) *Early Implementation Protocol for Inclusion of Candida Spp.;* 2019.

18. Ministry of Health Ghana National Drugs Programme (GNDP) Essential Medicines List Ministry of Health Seventh Edition (7th), 2017. Published 2017. Accessed January 19, 2021. https://www.moh.gov.gh/wp-content/uploads/2020/07/Ghana-EML-2017.pdf.

19. WHO. World Health Organization. World health organization model list of essential medicines. 2019; 21: 119-134. https://www.who.int/publications/i/item/WHOMVPEMPIAU2019.06.

20. Oladele RO, Osaigbovo II, Ayanlowo OO et al. The role of medical mycology societies in combating invasive fungal infections in low- and middle-income countries: a Nigerian model. *Mycoses.* 2019; 62: 16–21.